Compare Danaher Corporation (DHR) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Gartner Inc — how do they compare? Danaher Corporation trades at $204.78 (market cap $145.83B), while Gartner Inc trades at $181.63 (market cap $11.83B). The key difference: Danaher Corporation is far larger — about 12.3× Gartner Inc's market cap, and Danaher Corporation pays a 0.77% dividend while Gartner Inc pays none. Which is the better fit depends on your goals.
| DHR | IT | |
|---|---|---|
Market Cap | $145.83B | $11.83B |
Sector | Health | Technology |
52-Week High | $242.05 | $264.09 |
52-Week Low | $161.91 | $125.68 |
Enterprise Value | $168.04B | $13.57B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Gartner (IT) trades at $185.09, down 4.18% today, following a strong earnings beat in Q2 2026 with EPS of $4.37 versus $3.76 expected. The stock shows a bullish technical trend but trades above the consensus price target of $172.80. Recent news highlights a shareholder investigation and raised full-year EPS guidance, creating mixed sentiment amid strong profitability metrics like a 69.63% gross margin and 113.58% ROE.
The outlook is cautiously optimistic given earnings momentum and valuation discounts, but risks include consulting segment weakness, negative net cash flow trends, and the fiduciary investigation. Upside depends on sustained execution against guidance, while downside could stem from growth deceleration or legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
